About Jared Cumming
Jared Cumming is chief scientific officer at Matchpoint Therapeutics. Matchpoint develops covalent small-molecule medicines for immune diseases. He also serves as an Atlas Venture advisor. Atlas Venture builds biotechnology companies.
Before Matchpoint, he was senior vice president of drug discovery at LifeMine Therapeutics, where he worked on fungal natural products. Earlier, he held increasingly senior roles at Merck and Schering-Plough across neuroscience, immuno-oncology and oncology. He helped advance seven compounds into clinical trials. Ulevostinag reached Phase 2 in immuno-oncology, while verubecestat reached Phase 3 in Alzheimer’s disease. He has contributed to more than 110 patents and publications. He holds a chemistry doctorate from Johns Hopkins University and a chemistry bachelor’s degree from Williams College.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Jared Cumming in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Jared Cumming works with at each company, as listed on that company's latest Form D.


